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Purpose: The aim of this investigation was to exploit lens-specific glycated crystallins as an immunogen to detect human
glycated crystallins and their circulating autoantibodies in human serum during aging in relation to the development of
cataract.
Methods: Polyclonal antibodies were produced against human total lens proteins (40–80 years) in rabbits. The specificity
of the antibodies produced were determined by antibody capture assay using purified human lens crystallins (high
molecular weight fraction [HMW]+α, HMW+α-glycated, β, β-glycated, γ, and γ-glycated) as antigens. The cross-reactivity
of these lens specific antibodies against rat β-, β-glycated, γ-, and γ-glycated lens crystallins was also analyzed. A non-
competitive enzyme linked immunosorbent assay (ELISA) methodology was developed for the detection of circulating
lens crystallins in human sera using HMW+α, HMW+α-glycated, β-, and β-glycated crystallins from humans and γ- and
γ-glycated crystallins from rats as immobilized antigens. Circulating autoantibodies were also detected in human sera by
antibody capture assay. The methodology was validated by evaluating 60 human serum samples collected from cataract
patients and 30 human serum samples from apparently normal subjects belonging to the same age group.
Results: The polyclonal antibodies raised against human total lens proteins showed 90% and 65% cross-reactivity with rat
γ- and β-crystallins, respectively, by ELISA. Further, these polyclonal antibodies were capable of detecting both native
and in vitro synthesized glycated crystallins. Their IC50 values were observed to be (i) human total lens proteins (55 ng),
(ii) human HMW+α (16.45 ng), (iii) human HMW+α-glycated (273 ng), (iv) human β- (37.82 ng), (v) human β-glycated
(260 ng), (vi) rat γ- (105.34 ng), and (vii) rat γ-glycated (313 ng). The immunochemical analysis of human serum indicated
a significant change (p<0.001) in the levels of circulating β-glycated and γ-glycated crystallins in the age group of 40–80
years with respect to their control groups. However, there was no statistically significant change in the levels of HMW
+α-glycated crystallins in the age group of 40–80 years as compared to their age-matched controls. Notably, the levels of
serum γ-glycated crystallins were found to be threefold higher than that of HMW+α-glycated and β-glycated crystallins
in the age group of 70–80 years. Circulating autoantibodies to HMW+α-glycated, β-glycated, and γ-glycated crystallins
were detected in the serum of both apparently normal and cataract patients in the age group of 40–80 years by antibody
capture assay. The levels of these autoantibodies were significantly higher at every time point compared to their respective
controls. Autoantibodies to γ-glycated crystallins were found to be twofold and 3.2 fold higher as compared to the levels
of autoantibodies to β-glycated and HMW+α-glycated crystallins, respectively. Western blot and immunohistochemical
analysis substantiated the observations made in non-competitive ELISA.
Conclusions: During the course of aging, leakage of lens crystallins (HMW+α, HMW+α-glycated, β, β-glycated, γ, and
γ-glycated) elicit an immune response resulting in the formation of autoantibodies in cataract patients (40–80 years) as
compared to age matched controls. This is the first experimental report where polyclonal antibodies raised against lens-
specific glycated crystallins were capable of detecting the early leakage of glycated crystallins in human subjects. This
immunochemical approach has implications in the early detection of senile cataract.
Cataract includes any opacity of the lens from minor
opacities not interfering with vision to total opacity causing
blindness. Cataract is also classified as congenital, infantile,
and age-related (senile). Senile cataract remains a major cause
of blindness, affecting over 20 million of nearly 45 million
blind people worldwide with the highest incidence occurring
in developing countries [1-3]. There are no drugs available to
treat cataract. The only solution to get sight back is through
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surgery, which unfortunately is prohibitively expensive to
many  poor  people  [4-6]  in  developing  countries.  Sound
management of senile cataract depends upon early detection,
close monitoring, and timely surgical intervention.
Auto-immune  phenomena  are  thought  to  play  a
significant role in the initiation and propagation of several eye
diseases. However, there is little evidence so far to incriminate
immunological mechanisms in the pathogenesis of cataract in
humans  [7-10].  Lens  crystallins  are  an  example  of
immunologically  sequestered  proteins  with  high  organ
specificity and low species specificity [11]. During the past
decade, the concept of the high organ specificity and auto-
immunogenicity of these proteins has changed as subunits of
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2056α-crystallins  were  detected  in  the  rat  heart  [12],  skeletal
muscle [13], and central nervous system [14]. These proteins
also resemble small heat shock proteins [15]. The human
cataractous or normal lens has been used as source of antigenic
materials for investigations on circulating immunoglobulins
with  specificity  for  anti-lens  crystallins  [7,8,10].  These
developments  have  provided  a  strong  possibility  of
autoantibodies  to  lens  proteins  being  of  etiological
significance in the pathogenesis of cataract.
The Maillard reaction in cataract formation has also been
extensively  studied  in  both  the  aged  and  diabetic  lens.
Advanced  glycation  end  products  (AGEs)  of  various
derivations and molecular structures have been shown to be
markedly  elevated  [16-19].  A  significant  increase  in  the
concentration of AGE-like fluorophores in the aging human
lens was reported in our earlier work [20]. A major change
was observed during the age of 40–50 years with respect to
the formation of AGE-like fluorophores [20]. Anti-crystallin
autoantibodies have often been demonstrated in the serum of
healthy persons, especially in patients with cataract [8]. To
date, polyclonal and monoclonal anti-AGE antibodies have
been found to recognize various AGEs such as carboxymethyl
lysine  (CML),  pentosidine,  pyraline,  crossaline,
argpyrimidine,  and  imidazolone  as  the  major  epitopes  in
cataractous lens [21-25]. Recently, for the first time, we have
reported an immunochemical method for the detection and
quantification of glycated lens crystallins and their circulating
antibodies in diabetic rats [26]. No biochemical studies are
available in the contemporary literature to identify the specific
glycated lens crystallins against their specific antibodies in a
broader spectrum. In continuation of this work, the present
study  was  undertaken  to  develop  an  enzyme  linked
immunosorbent assay (ELISA) method for early detection of
human  glycated  lens  crystallins  and  their  circulating
antibodies during aging and cataractogenesis. Since human
lens crystallins are prone to posttranslational modifications,
which increase with aging [27], lens samples from donors of
different age groups were used for immunochemical detection
of glycated lens crystallins.
The prediction of the diseases has been correlated with
the level of antibodies, detection of which could foretell early
prognosis of the diseases [28]. To explore the feasibility of
using serum assays for lens proteins and to gain information
on the physiologic status of the lens during cataractogenesis
with respect to age, an enzyme immunoassay was developed
to  detect  the  high  molecular  weight  fraction  (HMW)+α-
glycated,  β-glycated,  and  γ-glycated  crystallins  and  their
circulating autoantibodies (IgG) in sera of cataract patients
during aging.
METHODS
Materials: Bovine serum albumin (BSA-fatty acid free, RIA
grade),  Freund’s  complete  adjuvant  (FCA),  Freund’s
incomplete adjuvant (FIA), fish gelatin, hemoglobin, anti-
rabbit  immunoglobulin  G  (IgG)  labeled  with  horseradish
peroxidase raised in goat (whole molecule), anti-human IgG
labeled with horseradish peroxidase raised in goat (whole
molecule), anti-rabbit IgG labeled with alkaline phosphatase
raised  in  goat  (whole  molecule),  3,  3′,  5,  5′
tetramethylbenzidine  (TMB),  urea  hydrogen  peroxide,  β-
cyclodextrin,  p-nitro-blue  tetrazolium  chloride  (NBT),  5-
bromo-4-chloro-3-indolyl  phosphate  toluidine  (BCIP),
Immobilon-P  transfer  membrane,  3,3′diaminobenzidine
(DAB), and Ultrafree-MC filters (molecular weight cut-off
limit–10 kDa) were all purchased from Sigma (St. Louis,
MO). Sephacryl-S-200 was sourced from Pharmacia (Upsala,
Sweden). Polystyrene microtiter ELISA plates were sourced
from  Greiner  (Nurtingen,  Germany).  Other  reagents  used
were of analytical grade.
Biological materials: Human lenses (20–80 years old) were
obtained from the Ramayamma International Eye Bank (a
member of the International Federation of Eye Banks and Eye
Bank  Association  of  India),  L  V  Prasad  Eye  Institute  in
Hyderabad,  India.  This  study  was  undertaken  with  the
approval of the ethical committee of L V Prasad Eye Institute.
Informed consent was also obtained for collecting the cadaver
lens through the Eye Bank of L V Prasad Eye Institute. The
lenses were stored at –80 °C until further use.
Human sera were obtained from cataract patients (n=60,
age: 40–80 years) and apparently normal subjects (n=30, age:
40–80 years) with their written consent. This study was also
undertaken with the approval of the ethical committee of
Sadhuram Eye Hospital in Hyderabad, India. Five milliliters
(ml) of blood was obtained from each subject. The serum was
separated  after  centrifugation  and  stored  at  −20  °C  until
further use.
Preparation of human lens homogenate: Aging human lenses
(20–80  years)  were  homogenized  individually  in  20  mM
phosphate buffer (pH 7.4) and centrifuged at 10,000x g for 30
min  at  4  °C.  Each  sample  was  separated  into  a  clear
supernatant and precipitate. The supernatant is referred to as
the “soluble fraction” and the precipitate as the “insoluble
fraction.” The precipitate obtained was further solubilized in
200 μl of 0.1 N NaOH. Both fractions were used for ELISA
(enzyme  linked  immunosorbent  assay)  and  western  blot
studies. Protein was estimated by the method of Lowry et al.
[29].
Isolation and synthesis of antigens: Cadaver human lenses
(n=4;  age:  20–30  years)  were  used  for  the  isolation  of
crystallins (HMW+α, β, and γ) using Sephacryl-S-200 gel
chromatography  (113×1.5  cm,  id)  [30].  Rat  β-  and  γ-
crystallins  were  isolated  by  the  method  described  earlier
[31]. Glycated proteins were synthesized in vitro as described
previously  [32].  Briefly,  proteins  (BSA,  hemoglobin,  and
human HMW+α-, β-, rat β-, and γ-crystallins; 0.1 g) were
dissolved separately along with glucose (1.6 mmol) and ribose
(0.7 mmol) in 5.0 ml of 400 mM sterile sodium phosphate
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conditions using a laminar flow cabinet. The vials were sealed
and placed in an air-circulating incubator at 37 °C for 10
weeks.  After  incubation,  each  mixture  was  dialyzed
extensively and concentrated using a spin column (Ultrafree-
MC filters, molecular weight cut-off limit-10 kDa; Sigma, St.
Louis, MO). The degree of glycation was assessed by the
trinitrobenzene sulfonic acid method (TNBS) [33] using the
following formula:
The synthetic AGEs were prepared in vitro as reported earlier
[20]. Briefly, a few amino acids, which are present in the
sequence for human γ-crystallins, were selected because of
their high susceptibility to glycation/AGE formation in the
course of cataract development. The following amino acid
mixture was incubated: 9.5 μmoles of lysine, 100 μmoles of
arginine, 23 μmoles of histidine, and 67 μmoles of tyrosine
along with 1.6 mmoles of glucose, 0.7 mmoles of ribose, all
in 5.0 ml of 400 mM phosphate buffer, pH 7.4. The samples
were processed under sterile conditions using the laminar flow
hood. The vials were sealed and placed in an air-circulating
incubator at 37 °C for 10 weeks. After incubation, the mixture
was  dialyzed  extensively  and  concentrated  using  a  spin
column  (Ultrafree-MC  filters,  molecular  weight  cut-off
limit-10 kDa).
Production and characterization of polyclonal antibodies to
human total lens proteins: Polyclonal antibodies were raised
against human total lens proteins (40–80 years) in two rabbits
[34]. Homogenates (10%) of the lyophilized lenses from 40,
60, and 80 years were mixed in the proportion of 1:2:1 (120 µg
[40  years]  +  240  µg  [60  years]  +120  µg  [80  years])  in
phosphate buffer (20 mM, pH 7.4) containing sodium chloride
(100 mM) and EDTA (25 mM). In this antigen mixture, the
ratio of soluble:insoluble lenticular protein was maintained as
2:1. A primer dose of 475 μg of the human total lens protein
per kg of body mass was given intradermally at multiple sites.
It was dissolved in sterile saline and emulsified with FCA in
a  1:1  ratio.  Later,  three  booster  doses  were  given  (250–
300 μg/kg body mass) intramuscularly in FIA. Blood was
collected from the animals after 30 days of primer dose and
10–12  days  after  the  booster  doses.  At  the  end  of  the
immunization schedule, the animals were sacrificed and blood
was  collected  by  cardiac  puncture.  Serum  was  separated,
lyophilized, and stored at –20 °C until further use.
The immune response of the immunogen was checked by
the double diffusion Ouchterlony technique [35]. Antisera
titers for pre-immune, primer, and for I, II, and III boosters
were determined by checkerboard analysis using the antibody
capture assay. An immunoglobulin G (IgG) fraction from
rabbit antisera was obtained by affinity purification using a
commercial Protein-G column as described earlier [36]. The
cross-reactivity of the affinity-purified antisera (raised against
human total lens proteins) were evaluated against rat β-, β-
glycated,  γ-,  and  γ-glycated  crystallins  and  also  against
glycated BSA, glycated hemoglobin (used as a test-control),
and synthetic AGEs by antibody capture assay. The affinity
purified antisera was used at a dilution of 1:40,000 for the
cross-reactivity studies. The % cross-reactivity calculations
were based on the following equation:
Non-competitive  ELISA:  The  affinity-purified  polyclonal
antibodies that were specific to human total lens proteins were
used to determine the levels of glycated crystallins (HMW
+α, β, and γ) in lens by non-competitive ELISA as described
in detail previously with slight modification [37]. Briefly, a
96  well  microtiter  plate  was  coated  with  their  respective
concentrations  of  purified  antigens  (human  HMW+α-
glycated or β-glycated, each 500 ng/50 μl per well; rat γ-
glycated,  1000  ng/50  μl  per  well)  dissolved  in  100  mM
carbonate buffer, pH 9.6, incubated overnight at 37 °C, and
washed three times with washing buffer (phosphate buffered
saline, 10 mM, pH 7.2 with 0.05% Tween-20 and 0.01%
sodium  azide,  PBS-T).  The  wells  were  blocked  for  non-
specific binding with 100 μl per well of 0.1% fish gelatin in
PBS (10 mM, pH 7.2) and washed three times. To each well,
50  μl  of  diluted  (1:40,000)  affinity-purified  polyclonal
antibodies to human total lens proteins were added, which had
been pre-incubated with test (human sera)/standard (different
concentrations [1–1000 ng] of the human HMW+α-glycated
or  β-glycated  or  rat  γ-glycated  crystallins  separately  as
antigens) for 1 h at room temperature before adding to the
plate. After 1 h of incubation on the plate, wells were washed
three times and later incubated at 37 °C for 1 h with 50 μl/well
of diluted (in 0.5% fish gelatin in PBS) horseradish peroxidase
labeled anti-rabbit IgG (1:6,000) raised in goat. The plates
were washed three times, and 150 μl per well of substrate
buffer was added, which consisted of 450 μl of TMB (10 mg/
ml of dimethyl sulfoxide) in 15 ml of 100 mM acetate buffer
(pH 5.0) containing 0.25% w/v (i.e., 37.5 mg) β-cyclodextrin
and 0.015% w/v (i.e., 2.25 mg) of urea hydrogen peroxide.
The reaction was terminated after 10 min by adding 50 μl per
well of 1.25 M H2SO4. The absorbance at 450 nm was recorded
using a SLT Spectra ELISA reader (SLT Lab Instruments,
Salzburg,  Austria).  Percent  binding  of  antibodies  versus
concentration of analyte (1–1000 ng) was used to generate an
inhibition  plot  using  linear  regression  analysis.  The
concentration of glycated crystallins (HMW+α, β, and γ) in
serum was expressed as µg/ml of serum. The concentration of
these  immunogens  is  the  amount  of  protein  (HMW+α-
glycated, β-glycated, and γ-glycated crystallins) required to
inhibit 50% (IC50) of the antibody binding.
Both glycated and non-glycated crystallins (HMW+α, β,
and γ) were analyzed by non-competitive ELISA where the
antigens  (human  HMW+α-,  HMW+α-glycated,  β-,  β-
glycated, and rat γ- and γ-glycated crystallins) were used as
analytes to displace the antibody. This study was performed
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([Conc. of standard required to produce 50% inhibition in the
immunoassay]/[Conc. of cross reacting material {antigens}
required to produce 50% inhibition in the immunoassay])x100
% Conjugation=(Conc. of ε-amino group in BSA)-(Conc. of 
ε-amino group in BSA after glycation)/(Conc. of ε-amino
group in BSA)to establish the 50% inhibition (IC50) level of the respective
parent antigens.
Antibody  capture  assay:  The  concentration  of  circulating
antibodies to HMW+α-glycated, β-glycated, and γ-glycated
crystallins in serum from cataract patients were analyzed by
antibody capture assay as described previously [32] using the
human HMW+α-glycated and β-glycated crystallins and rat
γ-glycated crystallins as antigens. The microtiter plate was
coated with their respective concentration of antigens (human
HMW+α-glycated  or  β-glycated  crystallin,  each  500  ng/
50  μl  per  well;  rat  γ-glycated,  1000  ng/  50  μl  per  well)
dissolved in 100 mM carbonate buffer (pH 9.6) incubated
overnight at 37 °C and washed three times with washing
buffer. The wells were blocked for non-specific binding with
100 μl per well of 0.1% fish gelatin in PBS (10 mM, pH 7.2).
The plates were washed three times, and sera (1:5,000) from
normal and cataract patients was added and incubated for 2 h
at 37 °C. After washing, plates were incubated at 37 °C for 1
h with 50 μl per well of diluted (0.5% fish gelatin in PBS)
horseradish peroxidase labeled anti-human IgG raised in goat
(1:12,000). The plates were washed three times, and 150 μl
per well of substrate buffer was added, which consisted of 450
μl of TMB (10 mg/ml of dimethyl sulfoxide) in 15 ml of 100
mM acetate buffer (pH 5.0) containing 0.25% w/v (i.e., 37.5
mg) β-cyclodextrin and 0.015% w/v (i.e., 2.25 mg) of urea
hydrogen peroxide was added to each well. The reaction was
terminated after 10 min by adding 50 μl of 1.25 M H2SO4 to
each well. The absorbance at 450 nm was recorded using a
SLT Spectra ELISA reader (SLT Lab Instruments). Affinity
purified antisera to human total lens proteins (1–1,000 ng)
were  used  to  generate  the  calibration  plot  for  crystallin-
specific  antibodies  (HMW+α-glycated,  β-glycated,  and  γ-
glycated  crystallins).  Results  were  expressed  as  µg/ml  of
serum.
Validation of ELISA methods: The ELISA methods developed
were validated by using serum samples obtained from cataract
patients  (n=60,  age:  40–80  years)  and  apparently  normal
subjects (n=30, age: 40–80 years).
Assessment  of  cataractogenesis:  Assessment  of
cataractogenesis with respect to glycation of lens crystallins
in aging human lens using affinity purified antisera to human
total lens proteins as primary antibody was performed by non-
competitive  ELISA,  western  blot,  and
immunohistochemistry.
Non-competitive  ELISA—Non-competitive  ELISA
was performed both in soluble and insoluble fractions. The
method has been described as detailed above.
Western blot—Western blot analysis in aging human
lens  fractions  (soluble  and  insoluble,  separately)  was
performed according to Towbin’s method [38] with slight
modification. This was performed using 50 μg lens protein
(both fractions separately) from different age groups (30–80
years). It was done to check the degree of glycation during the
progress of senile cataract in soluble and insoluble fractions
of lens proteins. Briefly, proteins separated by 12.5% SDS–
PAGE were electrophoretically transferred to Immobilon-P
transfer membrane (polyvinylidene fluoride membrane) using
a CONSORT electro-blotter system (Consort N.V., Turnhout,
Belgium). The membrane was soaked in 100% methanol for
30 s and washed with water for 2 min. It was then soaked in
Towbin’s transfer buffer (25 mM Tris, 192 mM glycine, and
20% methanol) for 30 min. The filter papers for sandwiching
the membrane and gel were cut to the dimensions of the gel
and were also soaked in Towbin’s transfer buffer for 30 min.
The transfer was performed at 1.1 mA/cm2 of gel, 50 V, and
150 W for 2 h at 21 °C. The membrane was washed three times
with washing buffer (10 mM PBS with 0.05% Tween-20) and
incubated in blocking buffer (3% fish gelatin in 10 mM PBS)
for 30 min and washed with washing buffer. It was incubated
overnight with blocking buffer containing diluted polyclonal
antibodies to human total lens proteins (1:1,000) with gentle
shaking at 21 °C. The membrane was washed three times with
washing buffer to remove unbound antibodies and incubated
for 1 h in alkaline phosphatase assay buffer (100 mM NaCl,
5 mM MgCl2, 100 mM Tris) containing diluted goat anti-
rabbit IgG coupled with alkaline phosphatase (1:5,000). The
membrane was washed three times with washing buffer and
incubated with BCIP/NBT developing solution (115 mmoles
of BCIP and 61 mmoles of NBT) until purple bands appeared.
The  color  development  was  arrested  by  immersing  the
membrane in water. The membrane was air dried for 20 min
and  stored.  It  was  photographed  using  a  digital  image
documentation system (UVItec, Cambridge, England).
Immunohistochemistry—Immunohistochemistry
study of the human lens was done with slight modification as
described earlier [25] using antibodies to human total lens
proteins as the primary antibody. Briefly, formalin-fixed and
paraffin-embedded human cadaver lens (40–80 years) were
cut into 3.0 µm thick sections and mounted on frost-free slides.
After overnight drying, the sections were kept in an oven at
56 °C for 25 min, deparaffinized with xylene, and rehydrated
in 95% of ethanol. To increase the immunoreactivity of the
epitopes, the sections were irradiated by microwave in 10 mM
sodium citrate buffer (pH 6.0) for 5 min at 800 W three times.
After washing with PBS-T (pH 7.4) for 15 min, the sections
were treated with 0.3% H2O2 for 15 min followed by thorough
washing with PBS-T. Blocking for non-specific binding was
done using 0.1% fish gelatin in PBS (10 mM, pH 7.2) with
normal rabbit serum for 30 min and washed for 15 min. All
steps were done at room temperature (25 °C) in a humid
chamber. Sections were incubated overnight with polyclonal
antibodies (1:1,000) to human total lens proteins in a humid
chamber at 4 °C. Controls were maintained by replacing just
the  primary  antibodies  and  both  primary  and  secondary
antibodies with PBS to determine non-specific binding of the
secondary  antibodies  and  inhibition  of  endogenous  tissue
peroxidase, respectively. After washing several times with
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(1:2,000),  horseradish  peroxidase  labeled  anti-rabbit  IgG
raised in goat, at 25 °C for 1 h in humid chamber. After
incubation with the secondary antibodies, peroxidase activity
was  detected  with  DAB  substrate  solution  (0.02%
diaminobenzidine, 0.005% H2O2, 10 mM Tris-HCL, pH 7.5).
Sections were incubated with DAB substrate solution for 30
min in a dark chamber at 25 °C followed by vigorous washing
with  distilled  water.  Sections  were  counter-stained  with
Mayer’s hematoxylin followed by washing with running tap
water.  Stained  sections  were  permanently  mounted  and
observed under compound microscope (Leica DM LB2; Leica
Microsystems,  Wetzlar,  Germany),  and  photographs  were
obtained using a digital camera.
Statistical analysis: The data was statistically analyzed by
using Sigma-Stat software version 5.0 (Sigma). The test of
significance was based on two-tailed Student’s t-test (p<0.05
and/or p<0.01).
RESULTS
Degree of glycation: The degree of glycation of crystallins
(human  HMW+α-  and  β-crystallins)  monitored  by  TNBS
assay  was  found  to  be  86%  at  the  end  of  12  weeks  of
incubation.
Characterization  of  antiserum:  Human  total  lens  proteins
(40–80 years) were used to produce polyclonal antibodies in
rabbits.  The  animals  showed  a  better  response,  and  the
antiserum titer of the second booster showed better response
at the dilution of 1:16 against human total lens proteins (40–
80 years) as determined by the Ouchterlony double diffusion
technique. Affinity-purified antibodies to human total lens
Figure 1. Titer determination curve for antibodies to human total lens
proteins by antibody capture assay. The affinity purified polyclonal
antibodies were diluted from 1:1,000 to 1:1,00,000 with a coating
parent antigen (human total lens proteins) concentration of 100, 250,
500, and 750 ng. The optimal dilution obtained was 1:40,000 with
250 ng of immobilized antigen, which gave an absorbance of 0.92.
Data points are mean values (n=5).
proteins (40–80 years) as determined by antibody capture
assay showed a titer of 1:40,000 at 250 ng per well of human
total lens proteins, which gave an absorbance of 0.92 (after
appropriate blank correction) (Figure 1). The higher dilution
of  anti-sera  (1:40,000)  indicates  better  specificity  of  the
antibodies  to  the  respective  antigen  (human  total  lens
proteins).
Antibodies to human total lens proteins (age 40–80 years)
showed cross-reactivity with rat β- (65%), β-glycated (45%),
γ- (90%), and γ-glycated (60%) crystallins as shown in Figure
2. These antibodies did not show any cross-reactivity with
glycated  BSA  and  glycated  hemoglobin  but  have  shown
immune response to the early week (I and II) products of
chemically synthesized AGEs as shown in Figure 3.
Figure 2. Cross reactivity of the affinity purified antisera raised
against human total lens proteins with rat β, β-glycated, γ-, and γ-
glycated crystallins, as determined by antibody capture assay. The
affinity purified antisera was used at a dilution of 1:40, 000. Data
points are mean values (n = 5).
Figure 3. Cross reactivity of the affinity purified antisera raised
against human total lens proteins with BSA-glycated, hemoglobin-
glycated, and synthetic AGEs, as determined by antibody capture
assay. The affinity purified antisera was used at a dilution of 1:40,
000. Data points are mean ± SD (n = 5).
Molecular Vision 2008; 14:2056-2066 <http://www.molvis.org/molvis/v14/a242> © 2008 Molecular Vision
2060Non-competitive ELISA: The standard displacement curve for
various  concentrations  (1–1,000  ng)  of  human  total  lens
proteins is shown in Figure 4. The inhibitory concentration at
50% antibody binding (IC50) for this protein was found to be
55 ng based on regression analysis, r2=0.99. The immune
response of antisera to human total lens proteins (40–80 years)
with both glycated and non-glycated crystallins (HMW+α,
β, and γ) was also calculated based on regression analysis,
which is summarized in Table 1. Further, it was noted that the
IC50 values for the lenticular crystallins were less than that of
their  respective  glycated  crystallins.  Among  the  native
crystallins (HMW+α, β, and γ), the IC50 values for HMW+α-
crystallin (16.45 ng) were found to be significantly lower as
depicted in Table 1.
Validation of ELISA: Circulating glycated crystallins (HMW
+α, β, and γ) were observed in sera of both apparently normal
subjects and cataract patients from different age groups (40–
80 years) as shown in Figure 5A-C. There was a statistically
significant change (p<0.001) in the levels of circulating β-
glycated and γ-glycated crystallins in the age group of 40–80
years with their respective controls. This was not true for the
HMW+α-glycated crystallins. Notably, the levels of serum γ-
glycated crystallins were found to be threefold higher than that
of HMW+α-glycated and β-glycated crystallins in the age
group of 70–80 years. Age matched controls also showed
significant  change  (p<0.05)  in  the  levels  of  glycated
crystallins during aging.
Circulating autoantibodies to glycated crystallins (HMW
+α, β, and γ) were detected in the serum of apparently normal
subjects and cataract patients in the age group of 40–50 years
as given in Figure 6A-C. The levels of these autoantibodies
were significantly higher (p<0.05 and p< 0.001) at every time
point  with  their  respective  controls.  Autoantibodies  to  γ-
glycated crystallins (Figure 6C) were found to be twofold and
3.2 fold higher as compared to the levels of autoantibodies to
β-glycated (Figure 6B) and HMW+α-glycated (Figure 6A)
crystallins, respectively.
Assessment of cataractogenesis: Apparent changes (p<0.05)
in the degree of glycation were found in the age group of 41–
50 years as compared to the age group of 20–40 years by the
ELISA  methodology  (Figure  7).  A  significant  change
(p<0.001) was observed from 51 to 60 years in the soluble
fraction of the lens while the insoluble fraction of the lens did
not show any change with respect to the degree of glycation.
Western blot analysis (Figure 8) illustrates a similar pattern
of  glycation  in  the  soluble  fraction  (Figure  8A)  of  aging
human  lens  as  observed  by  ELISA.  A  typical  trend  of
glycation was not observed in the insoluble fraction (Figure
8B) of aging human lens. Older lens (70–80 years) did show
a comparative degree of glycation in the insoluble fraction of
human lens as compared to the younger lens (30–50 years;
Figure  8B).  Immunohistochemical  analysis  indicated
enhanced  immunostaining  (intensity)  in  the  aged  (60–80
years) lens compare to 40-year-old lens. Control sections did
not show any immunostaining (Figure 9).
Figure 4. Standard displacement plot for human total lens proteins
as  determined  by  non-competitive  ELISA.  Percent  binding  of
antibodies versus concentration of human total lens proteins (1-1,000
ng) was used to generate an inhibition plot using linear regression
analysis. The affinity purified antisera was used at a dilution of
1:40,000. Data points are mean ± SD (n = 5).
TABLE 1. THE IC50 VALUES OF VARIOUS ANTIGENS AS DETERMINED BY NON-COMPETITIVE ELISA USING AFFINITY PURIFIED IgG
FRACTION FROM THE ANTISERA RAISED AGAINST HUMAN TOTAL LENS PROTEINS.
Antigens (Ag) IC50 (based on regression analysis) r2 value
Human total lens protein 55 ng 0.99
Human HMW+α 16.45 ng 0.99
Human HMW+α-gly 273 ng 0.95
Human β 37.82 ng 0.99
Human β-gly 260 ng 0.91
Rat γ 105.34 ng 0.98
Rat γ-gly 313 ng 0.97
Both glycated and non-glycated lens crystallins were used for the analysis. The affinity purified IgG fraction was used at a
dilution of 1:40, 000. The regression coefficients (r 2) indicate the linearity of the displacement curve.
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2061Figure 5. Profile of glycated human lens crystallins for all age groups
in peripheral circulation. A: Profile of HMW+α-glycated crystallins
in  peripheral  circulation  during  aging  with  respect  to
cataractogenesis as determined by non-competitive ELISA using
polyclonal  antibodies  raised  against  human  total  lens  proteins.
Values are mean±SD at every given time point (n=5). The asterisk
indicates that p<0.05, and the double asterisk indicates that p<0.001.
N-apparently normal subjects; P-cataract patients. B: Profile of β-
glycated  crystallins  in  peripheral  circulation  during  aging  with
respect to cataractogenesis as determined by non-competitive ELISA
using polyclonal antibodies raised against human total lens proteins.
Values are mean±SD at every given time point (n=5). The asterisk
indicates that p<0.05, and the double asterisk indicates that p<0.001.
N-apparently normal subjects; P-cataract patients. C: Profile of γ-
glycated  crystallins  in  peripheral  circulation  during  aging  with
respect to cataractogenesis as determined by non-competitive ELISA
using polyclonal antibodies raised against human total lens proteins.
Values are mean±SD at every given time point (n=5). The asterisk
indicates that p<0.05, and the double asterisk indicates that p<0.001.
N-apparently normal subjects; P-cataract patients.
Figure 6. Profile of circulating autoantibodies to glycated crystallins
in human serum. A: Profile of circulating autoantibodies to HMW
+α-glycated  crystallins  in  serum  during  aging  with  respect  to
cataractogenesis  as  determined  by  antibody  capture  assay  using
polyclonal  antibodies  raised  against  human  total  lens  proteins.
Values are mean±SD at every given time point (n=5). The asterisk
indicates that p<0.05, and the double asterisk indicates that p<0.001.
N-apparently  normal  subjects;  P-cataract  patients.  B:  Profile  of
circulating autoantibodies to β-glycated crystallins in serum during
aging with respect to cataractogenesis as determined by antibody
capture assay using polyclonal antibodies raised against human total
lens proteins. Values are mean±SD at every given time point (n=5).
The asterisk indicates that p<0.05, and the double asterisk indicates
that p<0.001. N-apparently normal subjects; P-cataract patients. C:
Profile  of  circulating  autoantibodies  to  γ-glycated  crystallins  in
serum during aging with respect to cataractogenesis as determined
by antibody capture assay using polyclonal antibodies raised against
human total lens proteins. Values are mean±SD at every given time
point  (n=5).  The  asterisk  indicates  that  p<0.05,  and  the  double
asterisk indicates that p<0.001. N-apparently normal subjects; P-
cataract patients.
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Considerable changes have been observed in aging human
lens with respect to opacity and coloration during the age of
40–50  years  with  respect  to  the  formation  of  AGE-like
fluorophores  as  reported  earlier  [26].  Hence,  selection  of
human lenses from the age group of 40–80 years was done to
raise polyclonal antibodies to human total lens proteins that
carry a varying degree of glycation during the natural course
of aging.
Higher specificity of these antibodies to human total lens
proteins (1:40,000) was observed as these comprise the major
lenticular structural proteins (α-, β-, and γ-crystallin). The
unique  combination  of  lens  crystallins  sourced  as  the
immunogen from the 40–80 years age group possibly resulted
in high titer polyclonal antibodies capable of detecting the
changing profile of crystallins (HMW+α, β, and γ) during the
course of aging. Production of polyclonal antibodies to human
total lens proteins resulted in antibodies that were capable of
cross-reacting  with  synthetically  prepared  rat  glycated
crystallins (β and γ) and AGEs. The higher percent of cross-
reactivity (90%) between rat γ- crystallins and antibodies to
human total lens proteins indicates that both share common
antigenic determinants. Based on the results of this cross-
reactivity  experiment,  rat  γ-crystallins  could  be  used
successfully as a substitute for human γ-crystallins. Human
hemoglobin and albumin are among the many proteins that
undergo non-enzymatic glycation (degree of glycation ~7%–
12%)  [39,40].  Their  levels  of  glycation  are  found  to  be
elevated during the diabetic condition [41]. Therefore, it was
necessary to rule out the possible cross-reactivity of these
polyclonal antibodies with glycated BSA and hemoglobin
before using these antibodies for the detection of lenticular
glycated proteins. The polyclonal antibodies to human total
lens  proteins  did  not  show  any  cross-reactivity  with
Figure 7. Immunochemical characterization of antibodies to human
total lens proteins towards the soluble and insoluble proteins of aging
human lens protein by non-competitive ELISA. Values are mean±SD
at every given time point (n=5). The asterisk indicates that p<0.05,
and the double asterisk indicates that p<0.001 in comparison to 20–
30-year-old lens fractions.
synthetically  prepared  glycated  BSA  and  glycated
hemoglobin (Figure 3).
The  vivid  range  of  specificity  of  these  polyclonal
antibodies has been supported by the IC50 values of glycated
and native crystallins (HMW+α, β, and γ; Table 1). This
indicated  lower  specificity  towards  glycated  proteins  as
compared to their native form in all cases since the major
epitopes possibly get masked due to glycation. The higher
sensitivity of antibodies to HMW+α-crystallins (IC50=16.45
ng) and lesser sensitivity to γ-crystallins (IC50=105.34 ng)
supports the evidence that older lens and cataract lens have
decreased levels of γ-crystallins in the soluble fraction and
increased levels of HMW+α-crystallins [42,43].
Several  studies  have  implied  that  cataract  is  an
autoimmune  disorder  [7,8,44-48].  In  mature  cataracts,
longstanding  leakage  of  crystallins  through  the  damaged
capsule is likely to occur. The immune system is thus exposed
to the crystallins, which are normally sequestered in the lens.
However,  those  crystallins  that  normally  occur  in  small
amounts outside the lens would be recognized as self and
therefore,  normally  would  not  evoke  an  autoimmune
response. Only the truly lens-specific crystallins would be
recognized as a non-self antigen and trigger autoantibodies
formation.  The  different  types  of  lens-specific  glycated
crystallins such as HMW+α, β, and γ in human sera from
cataract and apparently normal aging subjects (Figures 5A-C)
as well as their respective autoantibodies in the same set of
subjects (Figures 6A-C) were detected using affinity-purified
polyclonal  antibodies.  This  is  the  first  report  where  the
polyclonal antibodies raised against human total lens proteins
have  been  used  successfully  to  detect  the  lens-specific
glycated antigens and their circulating antibodies in human.
Since human lens crystallins are prone to post-translation
modifications, which increases with aging [20], the usage of
lens samples from different ages (40–80 years) may have the
Figure 8. Western blot analysis of antibodies to human total lens
proteins for all age groups towards the soluble and insoluble protein
fractions of aging human lens. Lens protein (50 μg) from (A) soluble
and (B) insoluble fractions was loaded and were separated by SDS-
PAGE (12.5%). Affinity purified antibodies were used at a dilution
of 1:1,000.
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2063wider  epitopes  for  different  type  of  AGEs.  Hence,  the
concentration  of  circulating  autoantibodies  to  glycated
crystallins (HMW+α, β, and γ) at the age of 40 years and
onwards  was  found  to  be  significantly  higher  in  the  test
samples in comparison to their age matched controls (Figures
6A-C). Further, in the age group of 50–60 years, the levels of
these autoantibodies reflected maximum change. This could
possibly be due to the vivid nature of polyclonal antibodies to
the early stage of glycation, which reflected enhanced levels
of glycated products as early as 40–50 years.
Questions concerning the role of glycation with respect
to the pathology of cataractogenesis during aging have been
assessed  in  the  present  study  using  ELISA,  western  blot
analysis, and immunohistochemical methods (Figure7, Figure
8,  and  Figure  9).  Both  western  blot  and  ELISA  results
confirmed  the  specificity  of  polyclonal  antibodies,
particularly  in  soluble  fraction  of  lens  protein,  where  the
obvious nature of glycation starts from 41 to 50 years (Figure
7). Thus, both quantitative and qualitative evidence indicated
a  greater  degree  of  glycation  in  the  soluble  fraction  in
comparison to the insoluble fraction of aging lenses (Figure 7
and Figure 8). This is the first report in which a greater degree
of  glycation  in  the  soluble  fraction  of  the  lens  has  been
observed when comparing to the insoluble fraction of lens by
using  the  polyclonal  antibodies  that  were  raised  against
human total lens proteins. Prior reports illustrate the presence
of more AGE-like products in the insoluble fraction of aging
and cataract lens compared to the soluble fraction of lens
[49,50] using antibodies to synthetic glycated BSA. Possibly
the use of the IgG fraction of booster III anti-sera raised
against naturally glycated total lens proteins are responsible
for this distinctive result wherein the nature of epitopes may
be different from the one generated synthetically.
It is interesting to note the obvious changes in the levels
of circulating autoantibodies against HMW+α-glycated, β-
glycated, and γ-glycated crystallins in the serum of cataract
patients in the age group of 40–50 years. A similar trend was
observed  for  circulating  antigens  and  β-glycated  and  γ-
glycated  crystallins  in  the  age  group  of  70–80  years  in
comparison to their age matched controls (Figure 5 and Figure
6). This reflects the leakage of these glycated crystallins at the
age  of  40–50  years  in  cataract  patients,  which  is  getting
neutralized by their respective autoantibodies at the early age
and reaching to the level of saturation by the age of 70–80
years in cataract patients. The higher level of serum γ-glycated
crystallins  and  their  autoantibodies  compared  to  other
glycated  crystallins  (Figure  5  and  Figure  6)  suggested  γ-
glycated  crystallins  to  be  more  immunogenic  than  the
glycated form of other crystallins, which is similar to the
observation recorded for their native forms [8,32]. The γ-
glycated  crystallins  seem  to  be  involved  in  very  early
cataractogenic  events  whereas  HMW+α-glycated  and  β-
glycated crystallins may be involved in later stages. HMW
+α-glycated  crystallins,  being  an  aggregated  molecule  as
compared to β-glycated and γ-glycated, may not evoke a high
level of antibody response in peripheral circulation (Figure 5
and Figure 6).
One of the major observations made in the present study
is the presence of antigens and autoantibodies to glycated
crystallins (HMW+α, β, and γ) in peripheral circulation in
cataract  patients  as  compared  to  age-matched,  apparently
normal subjects. γ-glycated crystallins may be considered a
more  suitable  biomarker  than  β-glycated  and  HMW+α-
glycated crystallins for the early detection of cataract during
aging.  However,  this  observation  needs  to  be  further
substantiated by extending the analysis to a larger sample size
of human subjects in relation to cataract development as a
function of aging.
The experimental findings of the present investigation
may  have  practical  relevance  in  detecting  the  glycated
crystallins (HMW+α-, β-, and γ-crystallins) and their specific
autoantibodies as a biochemical marker for early detection of
cataract in human subjects. Further, the immunoanalytical
methods developed might have immense value in adopting
appropriate  strategies  to  delay  the  process  of  cataract
formation by nutritional and metabolic interventions.
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